Does SANDOSTATIN LAR DEPOT Cause Malignant neoplasm progression? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Malignant neoplasm progression have been filed in association with SANDOSTATIN LAR DEPOT. This represents 12.5% of all adverse event reports for SANDOSTATIN LAR DEPOT.
6
Reports of Malignant neoplasm progression with SANDOSTATIN LAR DEPOT
12.5%
of all SANDOSTATIN LAR DEPOT reports
4
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From SANDOSTATIN LAR DEPOT?
Of the 6 reports, 4 (66.7%) resulted in death.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SANDOSTATIN LAR DEPOT. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does SANDOSTATIN LAR DEPOT Cause?
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)